![]() | Tracey ClarkPO Box 533, Physiotherapy Department, Westmead Hospital, Wentworthville, NSW 2145, Australia. | Pfizer Inc., BioMedicine Design, Groton, Connecticut. | BioMedicine Design, ... |
KOL Resume for Tracey Clark
Year | |
---|---|
2022 | PO Box 533, Physiotherapy Department, Westmead Hospital, Wentworthville, NSW 2145, Australia. |
2020 | Pfizer Inc., BioMedicine Design, Groton, Connecticut. |
2018 | BioMedicine Design, Pfizer Worldwide Research and Development, 558 Eastern Point Road, 06340, Groton, CT, USA |
2013 | Worldwide Research and Development, Pfizer Inc., Eastern Point Road, Groton, CT 06340, United States |
Tracey Clark: Influence Statistics
Concept | World rank |
---|---|
adc pf06804103 | #25 |
pf06804103 | #42 |
fgf21 variant | #64 |
Open the FULL List in Excel | |
Prominent publications by Tracey Clark
PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
[ PUBLICATION ]
The approval of ado-trastuzumab emtansine (T-DM1) in HER2+ metastatic breast cancer validated HER2 as a target for HER2-specific antibody-drug conjugates (ADC). Despite its demonstrated clinical efficacy, certain inherent properties within T-DM1 hamper this compound from achieving the full potential of targeting HER2-expressing solid tumors with ADCs. Here, we detail the discovery of PF-06804103, an anti-HER2 ADC designed to have a widened therapeutic window compared with T-DM1. We ...
Known for Drug Conjugate | Her2 Adc | Breast Neoplasms | Specific Antibody | Cleavable Linker |
Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors
[ PUBLICATION ]
The synthesis and biological evaluation of novel Tie-2 kinase inhibitors are presented. Based on the pyrrolopyrimidine chemotype, several new series are described, including the benzimidazole series by linking a benzimidazole to the C5-position of the 4-amino-pyrrolopyrimidine core and the ketophenyl series synthesized by incorporating a ketophenyl group to the C5-position. Medicinal chemistry efforts led to potent Tie-2 inhibitors. Compound 15, a ketophenyl pyrrolopyrimidine urea analog ...
Known for Solid Tumors | Biological Evaluation | Kinase Inhibitors | Pyrimidines Pyrroles | Drug Discovery |
Pharmacological administration of FGF21 analogues has shown robust body weight reduction and lipid profile improvement in both dysmetabolic animal models and metabolic disease patients. Here we report the design, optimization, and characterization of a long acting glyco-variant of FGF21. Using a combination of N-glycan engineering for enhanced protease resistance and improved solubility, Fc fusion for further half-life extension, and a single point mutation for improving ...
Known for Fgf21 Variant | Intact Protein | Monoclonal Antibodies | Halflife Extension | Single Point Mutation |
INTRODUCTION: In response to the COVID-19 pandemic, telehealth has been rapidly implemented in outpatient services worldwide. However, little is known about the experiences of telehealth in a tertiary outpatient physiotherapy setting.
OBJECTIVE: 1) describe the experience of physiotherapists and patients who utilized telehealth services in a tertiary health facility; and 2) identify the challenges and opportunities of physiotherapy service provision via telehealth in a tertiary health ...
Key People For Her2 Adc
Tracey Clark:Expert Impact
Concepts for whichTracey Clarkhas direct influence:Her2 adc, Pyrimidines pyrroles, Halflife extension, Fgf21 variant, Adc pf06804103, Tie2 structure, Antibody drug, Dawley receptor.
Tracey Clark:KOL impact
Concepts related to the work of other authors for whichfor which Tracey Clark has influence:Marine origin, Hepatic fgf21, Pyrrolopyrimidine derivatives, Her2 adc, Therapeutic medicine, Rat serum, Quantitative comparison.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |